RecruitingPhase 3NCT07010471
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
Studying OBSOLETE: Early infantile epileptic encephalopathy without suppression burst
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Praxis Precision Medicines
- Principal Investigator
- Medical DirectorPraxis Precision Medicines
- Intervention
- 1.0mg/kg/day PRAX-562(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 2-65 years · All sexes
- Timeline
- 2025 – 2027
Study locations (5)
- Praxis Research Site, La Jolla, California, United States
- Praxis Research Site, Gulf Breeze, Florida, United States
- Praxis Research Site, Chevy Chase, Maryland, United States
- Praxis Research Site, Roseville, Minnesota, United States
- Praxis Research Site, São Paulo, Brazil
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07010471 on ClinicalTrials.gov